Post-IVTA endophthalmitis on the rise

Article

The incidence of sterile endophthalmitis occurring subsequent to an intravitreal injection of triamcinolone acetonide (IVTA) is increasing, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

The incidence of sterile endophthalmitis occurring subsequent to an intravitreal injection of triamcinolone acetonide (IVTA) is increasing, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

Jonathan Jonisch, MD of the department of ophthalmology at North Shore-Long Island Jewish Health System, New York, US and colleagues conducted a retrospective chart review of 554 eyes undergoing IVTA injections in a vitreoretinal clinic over a 19 month period, from 1 January 2005 to 31 July 2006.

During the study period, 1.9% (n=11) of the eyes undergoing IVTA developed endophthalmitis, and none of the affected eyes tested positive for bacterial or fungal organisms. However, of the 97 eyes undergoing IVTA during the final three month period of 1 May–31 July 2006, 9.3% (n=9) of treated eyes developed sterile endophthalmitis, representing a statistically significant jump in cases over the beginning of the study period. Phials used for these later patients were found to be negative for bacterial endotoxin.

The researchers concluded that, although there was a demonstrable cluster of endophthalmitis cases over a short period during the overall study period, there was no immediately apparent reason for this, as the IVTA phials were found to be free of contamination.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.